Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
Nanchahal J. et al, (2018), EBioMedicine, 33, 282 - 288
Standard wound management versus negative-pressure wound therapy in the treatment of adult patients having surgical incisions for major trauma to the lower limb-a two-arm parallel group superiority randomised controlled trial: protocol for Wound Healing in Surgery for Trauma (WHIST).
Achten J. et al, (2018), BMJ Open, 8
Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert.
Lee G. et al, (2018), Proc Natl Acad Sci U S A, 115, E4463 - E4472
HMGB1 accelerates regeneration of multiple tissues by transitioning stem cells to G(Alert)
Lee G. et al, (2018), AUSTRALASIAN JOURNAL OF DERMATOLOGY, 59, 83 - 83
Method of treating a localized fibrotic disorder using an IL-33 antagonist
NANCHAHAL J. et al, (2018)
What do we know about managing Dupuytren's disease cost-effectively?
Dritsaki M. et al, (2018), BMC Musculoskelet Disord, 19
HMGB1 Accelerates Regeneration of Multiple Tissues By Transitioning Stem Cells to G(Alert)
Lee G. et al, (2017), BLOOD, 130
HMGB1 accelerates regeneration of multiple tissues by transitioning stem cells to G(Alert)
Lee G. et al, (2017), JOURNAL OF BONE AND MINERAL RESEARCH, 32, S48 - S48
A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.
Ng M. et al, (2017), Am J Hum Genet, 101, 417 - 427
Does negative-pressure wound therapy influence subjacent bacterial growth? A systematic review.
Glass GE. et al, (2017), J Plast Reconstr Aesthet Surg, 70, 1028 - 1037
Anti-TNF Therapy
Udalova I. et al, (2017), Myeloid Cells in Health and Disease: A Synthesis, 637 - 648
Gastrocnemius Muscle Flaps for Lower Limb Reconstruction
Atherton D. et al, (2017), FLAPS: PRACTICAL RECONSTRUCTIVE SURGERY, 224 - 229
Recurrence of Dupuytren's contracture: A consensus-based definition.
Kan HJ. et al, (2017), PLoS One, 12
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.
Nanchahal J. et al, (2017), Wellcome Open Res, 2
Tonometry as an outcome measure for early Dupuytren's disease
BALL C. et al, (2016), Dupuytren Disease and Related Diseases - The Cutting Edge